Full Generic Medicine Info
Dosage/Direction for Use

Palliative treatment of malignant breast neoplasms in postmenopausal women
Adult: 10-20 mg daily.
Renal impairment: Use with caution.
Hepatic impairment: Use with caution.

Advanced prostatic carcinoma
Adult: 1-3 mg daily.
Renal impairment: Use with caution.
Hepatic impairment: Use with caution.

Menopausal atrophic vaginitis
Adult: 1 mg daily as pessaries.
Renal impairment: Use with caution.
Hepatic impairment: Use with caution.
Pregnancy, thromboembolic disease, porphyria; breast cancer (with exceptions).
Special Precautions
CV disease; hepatic and renal impairment.
Adverse Reactions
GI disturbances, CV and CNS side effects, jaundice, impotence. Feminization, impotence and gynaecomastia in men. Withdrawal and breakthrough bleeding, irregular menses, amenorrhoea in women. Hypercalcaemia, chloasma, keratoconus, contact lenses intolerance, altered carbohydrate metabolism, loss of diabetic control.
Drug Interactions
Anticoagulants, liver enzyme inducers, corticosteroids.
Lab Interference
Elevated liver function tests.
Diethylstilbestrol is a synthetic nonsteroidal oestrogen with effects similar to natural oestrogens. It inhibits luteinising hormone secretion by the pituitary, thereby inhibiting testosterone secretion.
Absorption: Readily absorbed from the GI tract.
Metabolism: Slowly metabolised in the liver.
Excretion: Excreted in the urine and faeces, mainly as the glucuronide.
CIMS Class
Oestrogens & Progesterones & Related Synthetic Drugs
ATC Classification
G03CC05 - diethylstilbestrol ; Belongs to the class of estrogens in combination with other drugs used in estrogenic hormone preparations.
G03CB02 - diethylstilbestrol ; Belongs to the class of plain synthetic estrogens.
L02AA01 - diethylstilbestrol ; Belongs to the class of estrogens.
Disclaimer: This information is independently developed by CIMS based on diethylstilbestrol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in